Wealthfront Advisers LLC significantly increased its position in Amgen Inc. during the third quarter, raising its stake by 22.4%. The investment firm now holds 70,233 shares of Amgen, valued at an estimated $19.82 million. This move comes as Amgen reported robust fourth-quarter earnings, surpassing analyst expectations. Furthermore, the biotechnology giant demonstrated its commitment to shareholder returns by increasing its quarterly dividend to $2.52 per share. Despite a recent 3.0% dip in Amgen's stock price, Wealthfront's expanded holding suggests confidence in the company's underlying financial strength and future prospects. This strategic increase by a prominent advisory firm highlights Amgen's appeal to institutional investors.
Get AI-powered deep analysis for every story with a paid subscription
Upgrade for Analysis